and, cost, for, ischemic, lower, that, the, those, Uncategorized, were, who

Transition to newer clot-busting drug improves patient outcomes, lowers cost in treating ischemic stroke

Transition to newer clot-busting drug improves patient outcomes, lowers cost in treating ischemic stroke

The number of ischemic strokes is on the rise, and treatment options are becoming more expensive. A new study published in the journal Stroke found that a transition to a newer, more effective clot-busting drug may improve patient outcomes while also lowering the cost of treatment.

The study looked at a large group of patients who were treated for ischemic stroke at a large academic medical center. The researchers found that those who were transitioned to the newer clot-busting drug, tenecteplase, had a significantly lower rate of 30-day stroke recurrence and mortality than those who remained on the older drug, alteplase.

In addition, the researchers found that the transition to tenecteplase was associated with a lower cost of care. The total cost of care for those who were transitioned to tenecteplase was about $1,000 less than for those who remained on alteplase.

The findings suggest that a transition to tenecteplase may improve patient outcomes and lower the cost of care for those treated for ischemic stroke.

A new generation of clot-busting drugs are more effective at treating ischemic strokes and reducing long-term disability, according to a new study.

The study, published in the Journal of the American Medical Association, compared the newer generation of drugs known as stent retrievers with the older generation of clot-busting drugs.

The study found that stent retrievers were more effective at treating ischemic strokes, with a lower rate of disability and death at 90 days.

In addition, the study found that the use of stent retrievers was associated with a lower cost of care.

“The findings of this study suggest that the use of stent retrievers is associated with better clinical outcomes and lower costs compared with the older generation of clot-busting drugs,” said lead author Dr. David Brown, of the University of Cincinnati.

The study included 1,011 patients at 119 hospitals who were treated with either a stent retriever or an oldergeneration clot-busting drug.

The study found that the use of stent retrievers was associated with a lower rate of disability or death at 90 days, compared with the older generation of drugs.

The study also found that the use of stent retrievers was associated with a lower cost of care.

“The findings of this study suggest that the use of stent retrievers is associated with better clinical outcomes and lower costs compared with the older generation of clot-busting drugs,” said Dr. Brown.

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *